Capsule endoscopy (CE), introduced in 2000 and FDA-approved in 2001, remains a valuable tool for diagnosing gastrointestinal (GI) lesions, particularly in areas inaccessible to traditional endoscopy. While CE offers non-invasive imaging and improves detection of small bowel diseases and obscure GI bleeding, its widespread use is hindered by limitations such as lack of therapeutic capabilities, inability to obtain biopsies, reliance on peristalsis for movement, and time-consuming image interpretation.
Trending
- Digital self-management programme for pain, fatigue and faecal incontinence in inflammatory bowel disease: cost-effectiveness analysis of the IBD-BOOST randomised controlled trial (BMJ)
- Clinicians Encouraged to ‘See C. diff Differently’ as Diagnostics, Resistance Patterns, and Therapeutic Tools Shift (GI & Endoscopy News)
- AGA, ACG Express Concerns About New American Cancer Society Recommendations (GI & Endoscopy News)
- In vitro development of the Autonomous Colonoscope Robot System (ACRS) for fully automated colonoscope insertion (Nature)
- Zobair Younossi, MD, on Global Consensus Recommendations for MASLD/MASH (HMP Global Learning Network )
- Recommending Blood Tests for CRC Without Guardrails Risks Confusion (MedPage Today)
- Gut Microbiome Could Remain Disrupted For Over a Decade After Polyp Removal (ScienceAlert)
- Why physician is not the same as provider (KevinMD)
